Ginsenoside Rg1 exerts anti‑apoptotic effects on non‑alcoholic fatty liver cells by downregulating the expression of SGPL1

Li,Guiming; Xie,Hongqing; Cao,Xiaodie; Ma,Chong; Li,Yan; Chen,Li

doi:10.3892/mmr.2022.12694

Ginsenoside Rg1 exerts anti‑apoptotic effects on non‑alcoholic fatty liver cells by downregulating the expression of SGPL1

Authors:
- Guiming Li
- Hongqing Xie
- Xiaodie Cao
- Chong Ma
- Yan Li
- Li Chen
View Affiliations

Affiliations: Department of Geriatrics, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650100, P.R. China, Department of Pathophysiology, Medical School, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China
Published online on: March 22, 2022 https://doi.org/10.3892/mmr.2022.12694
Article Number: 178
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic fatty liver disease (NAFLD) has a high incidence, and can lead to liver cirrhosis and even hepatocellular carcinoma in severe cases. To the best of our knowledge, there is currently no safe and effective treatment for the management of this disease. Ginsenoside Rg1 (Rg1) is an active monomer derived from ginseng and notoginseng. In the present study, HHL‑5 hepatocytes were used to establish an in vitro cell model of NAFLD by medium‑ and long‑chain fat emulsion treatment, and the effects of Rg1 on adipose accumulation, apoptosis and the expression levels of apoptosis‑related proteins in HHL‑5 hepatocytes were examined. The results demonstrated that Rg1 inhibited the accumulation of fat in HHL‑5 cells, while inhibiting apoptosis, and Rg1 downregulated the expression levels of the pro‑apoptotic protein Bax and upregulated the expression levels of the anti‑apoptotic protein Bcl‑2, indicating that Rg1 could promote the stability or integrity of mitochondria and exert an anti‑apoptotic effect by regulating Bcl‑2 family proteins. In addition, Rg1 markedly downregulated the expression levels of sphingosine‑1‑phosphate lyase 1 (SGPL1), a key enzyme in the sphingosine signaling pathway, in HHL‑5 cells with steatosis, and increased the expression levels of the downstream pro‑survival signals phosphorylated (p‑)Akt and p‑Erk1/2. Furthermore, overexpression of SGPL1 abolished the anti‑apoptotic effect of Rg1 on SGPL1‑overexpressing HHL‑5 cells with steatosis, and downregulated the expression levels of pro‑survival proteins, such as Bcl‑2, p‑Akt and p‑Erk1/2, whereas the expression levels of pro‑apoptotic Bax were markedly increased. In conclusion, although there are some reports regarding the protective effect of Rg1 on fatty liver cells, to the best of our knowledge, the present study is the first to report that Rg1 may exert an anti‑apoptotic effect on fatty liver cells by regulating SGPL1 in the sphingosine signaling pathway. Rg1 is the main component of the prescription drug Xuesaitong in China; therefore, the findings of the present study may provide a theoretical molecular basis for the use of Rg1 or Xuesaitong in the treatment of patients with NAFLD.

View Figures

View References

1	Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM and Sanyal AJ: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the american association for the study of liver diseases. Hepatology. 67:328–357. 2018. View Article : Google Scholar : PubMed/NCBI
2	Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, Yamaguchi K and Itoh Y: Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012. J Gastroenterol. 50:95–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, et al: Modeling nafld disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, And United States for the period 2016–2030. J Hepatol. 69:896–904. 2018. View Article : Google Scholar : PubMed/NCBI
4	Li Z, Xue J, Chen P, Chen L, Yan S and Liu L: Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies. J Gastroenterol Hepatol. 29:42–51. 2014. View Article : Google Scholar : PubMed/NCBI
5	Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A and Olinga P: Investigating fibrosis and inflammation in an ex vivo NASH murine model. Am J Physiol Gastrointest Liver Physiol. 318:G336–G351. 2020. View Article : Google Scholar : PubMed/NCBI
6	Buzzetti E, Pinzani M and Tsochatzis EA: The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 65:1038–1048. 2016. View Article : Google Scholar : PubMed/NCBI
7	Li J, Yang C, Zhang S, Liu S, Zhao L, Luo H, Chen Y and Huang W: Ginsenoside Rg1 inhibits inflammatory responses via modulation of the nuclear factor-κB pathway and inhibition of inflammasome activation in alcoholic hepatitis. Int J Mol Med. 41:899–907. 2018.PubMed/NCBI
8	Wang ZL, Chen LB, Qiu Z, Chen XB, Liu Y, Li J, Wang L and Wang YP: Ginsenoside Rg1 ameliorates testicular senescence changes in D-gal-induced aging mice via anti-inflammatory and antioxidative mechanisms. Mol Med Rep. 17:6269–6276. 2018.PubMed/NCBI
9	Tang F, Lu M, Yu L, Wang Q, Mei M, Xu C, Han R, Hu J, Wang H and Zhang Y: Inhibition of TNF-α-mediated NF-κB activation by ginsenoside Rg1 contributes the attenuation of cardiac hypertrophy induced by abdominal aorta coarctation. J Cardiovasc Pharmacol. 68:257–264. 2016. View Article : Google Scholar : PubMed/NCBI
10	Tang YL, Zhou Y, Wang YP, He YH, Ding JC, Li Y and Wang CL: Ginsenoside Rg1 protects against sca-1⁺ HSC/HPC cell aging by regulating the SIRT1-FOXO3 and SIRT3-SOD2 signaling pathways in a γ-ray irradiation-induced aging mice model. Exp Ther Med. 20:1245–1252. 2020. View Article : Google Scholar : PubMed/NCBI
11	Huang SL, He XJ, Li ZF, Lin L and Cheng B: Neuroprotective effects of ginsenoside Rg1 on oxygen-glucose deprivation reperfusion in PC12 cells. Pharmazie. 69:208–211. 2014.PubMed/NCBI
12	Wang J, Hou J, Lei H, Fu J, Pan Y and Liu J: Synergistic neuroprotective effect of microglial-conditioned media treated with geniposide and ginsenoside Rg1 on hypoxia injured neurons. Mol Med Rep. 12:5328–5334. 2015. View Article : Google Scholar : PubMed/NCBI
13	Xiao Q, Zhang S, Yang C, Du R, Zhao J, Li J, Xu Y, Qin Y, Gao Y and Huang W: Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in HepG2 cells via the AMPK/NF-κB pathway. Int J Endocrinol. 2019:75148022019. View Article : Google Scholar : PubMed/NCBI
14	Peng X, Huang D, Yan M and Peng S: Ginsenoside Rg1 improves liver function by regulating fat metabolism in rats with non-alcoholic fatty liver disease. Chin J Pathophysiol. 31:864–870. 2015.
15	Xiao Y, Hou YH, Yin X, Kang F, Li SD, Yang SK and Tao JP: Ginsenoside Rg1 protects against hepatocyte apoptosis in a rat model of non-alcoholic fatty liver disease. Chin J Tissue Eng Res. 23:384–390. 2019.
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Kwong E, Li Y, Hylemon PB and Zhou H: Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sin B. 5:151–157. 2015. View Article : Google Scholar : PubMed/NCBI
18	Strub GM, Maceyka M, Hait NC, Milstien S and Spiegel S: Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol. 688:141–155. 2010. View Article : Google Scholar : PubMed/NCBI
19	Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64:73–84. 2016. View Article : Google Scholar : PubMed/NCBI
20	Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH and Loomba R: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 13:643–654. e1–9; quiz e39-40. 2015. View Article : Google Scholar : PubMed/NCBI
21	Warren CFA, Wong-Brown MW and Bowden NA: BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 10:1772019. View Article : Google Scholar : PubMed/NCBI
22	Edlich F: BCL-2 proteins and apoptosis: Recent insights and unknowns. Biochem Biophys Res Commun. 500:26–34. 2018. View Article : Google Scholar : PubMed/NCBI
23	Gao Y, Chu S, Zhang Z and Chen N: Hepataprotective effects of ginsenoside Rg1-a review. J Ethnopharmacol. 206:178–183. 2017. View Article : Google Scholar : PubMed/NCBI
24	Xu Y, Yang C, Zhang S, Li J, Xiao Q and Huang W: Ginsenoside Rg1 protects against Non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation. Biol Pharm Bull. 41:1638–1644. 2018. View Article : Google Scholar : PubMed/NCBI
25	Hou Y, Gu D, Peng J, Jiang K, Li Z, Shi J, Yang S, Li S and Fan X: Ginsenoside Rg1 regulates liver lipid factor metabolism in NAFLD model rats. ACS Omega. 5:10878–10890. 2020. View Article : Google Scholar : PubMed/NCBI
26	Cobbina E and Akhlaghi F: Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 49:197–211. 2017. View Article : Google Scholar : PubMed/NCBI
27	Arrese M, Cabrera D, Kalergis AM and Feldstein AE: Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 61:1294–1303. 2016. View Article : Google Scholar : PubMed/NCBI
28	Qi J, Kim JW, Zhou Z, Lim CW and Kim B: Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. Am J Pathol. 190:68–81. 2020. View Article : Google Scholar : PubMed/NCBI
29	Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E and Bailly-Maitre B: Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 69:927–947. 2018. View Article : Google Scholar : PubMed/NCBI
30	Maceyka M, Harikumar KB, Milstien S and Spiegel S: Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 22:50–60. 2012. View Article : Google Scholar : PubMed/NCBI
31	Yamada A, Nagahashi M, Aoyagi T, Huang WC, Lima S, Hait NC, Maiti A, Kida K, Terracina KP, Miyazaki H, et al: ABCC1-Exported Sphingosine-1-phosphate, produced by sphingosine kinase 1, shortens survival of mice and patients with breast cancer. Mol Cancer Res. 16:1059–1070. 2018. View Article : Google Scholar : PubMed/NCBI
32	Matula K, Collie-Duguid E, Murray G, Parikh K, Grabsch H, Tan P, Lalwani S, Garau R, Ong Y, Bain G, et al: Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer. 15:7622015. View Article : Google Scholar : PubMed/NCBI
33	Degagné E, Pandurangan A, Bandhuvula P, Kumar A, Eltanawy A, Zhang M, Yoshinaga Y, Nefedov M, de Jong PJ, Fong LG, et al: Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest. 124:5368–5384. 2014. View Article : Google Scholar : PubMed/NCBI
34	Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B and Cuvillier O: First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: Implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 11:1841–1851. 2012. View Article : Google Scholar : PubMed/NCBI
35	Dai G, Jiang Z, Bai Y, Zhang Q, Zhu L, Bai X, Ju W and Pan R: Pharmacokinetic herb-drug interaction of Xuesaitong dispersible tablet and aspirin after oral administration in blood stasis model rats. Phytomedicine. 26:62–68. 2017. View Article : Google Scholar : PubMed/NCBI
36	Li F, Zhao H, Han Z, Wang R, Tao Z, Fan Z, Zhang S, Li G, Chen Z and Luo Y: Xuesaitong may protect against ischemic stroke by modulating microglial phenotypes and inhibiting neuronal cell apoptosis via the STAT3 signaling pathway. CNS Neurol Disord Drug Targets. 18:115–123. 2019. View Article : Google Scholar : PubMed/NCBI
37	Chen H, Cao H, Guo X, Zhao M, Xia Q, Chen B, Zhao T and Gao W: Naoxuekang, Xinnaoshutong and Xuesaitong capsules for treating stroke: A protocol for a randomised controlled trial. BMJ Open. 7:e0159832017. View Article : Google Scholar : PubMed/NCBI
38	Yang X, Xiong X, Wang H, Yang G and Wang J: Xuesaitong soft capsule (Chinese patent medicine) for the treatment of unstable angina pectoris: A meta-analysis and systematic review. Evid Based Complement Alternat Med. 2013:9483192013. View Article : Google Scholar : PubMed/NCBI
39	Xu TZ, Shen XY, Sun LL, Chen YL, Zhang BQ, Huang DK and Li WZ: Ginsenoside Rg1 protects against H2O2-induced neuronal damage due to inhibition of the NLRP1 inflammasome signalling pathway in hippocampal neurons in vitro. Int J Mol Med. 43:717–726. 2019.PubMed/NCBI
40	Li H, Xu J, Wang X and Yuan G: Protective effect of ginsenoside Rg1 on lidocaine-induced apoptosis. Mol Med Rep. 9:395–400. 2014. View Article : Google Scholar : PubMed/NCBI
41	Zhang Y, Ding S, Chen Y, Sun Z, Zhang J, Han Y, Dong X, Fang Z and Li W: Ginsenoside Rg1 alleviates lipopolysaccharide-induced neuronal damage by inhibiting NLRP1 inflammasomes in HT22 cells. Exp Ther Med. 22:7822021. View Article : Google Scholar : PubMed/NCBI